People
Centers & Teams
Centers & Teams
Find information about our Centers and Teams.
Behavioral health
Cardiovascular health
Center for Evaluation and Survey Research
Critical Care Research Center
Diabetes
International Diabetes Center
Orthopedic trauma
Primary care, pediatrics
Research Methodology Group
TRIA Research and Education Center
Worksite and occupational health
Cancer Research Center
Center for Chronic Care Innovation
Community and population health
Dental and oral health
Health economics
Neuroscience Research Centers
Pregnancy and child health
Pulmonology
Rheumatology
Vaccines
Knowledge
About
About
FAQ
HealthPartners Institute
People
Centers & Teams
Knowledge
About
HealthPartners Institute
J. L. Wade
All authors
About
Publications While At HealthPartners
selected publications
Journal Article
Phase III randomized, placebo-controlled clinical trial of donepezil for treatment of cognitive impairment in breast cancer survivors after adjuvant chemotherapy (WF-97116)
.
Journal of Clinical Oncology.
2024
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: the MAESTRO study
.
Cancer.
2020
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial
.
Cancer medicine.
2020
Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study
.
Journal of Clinical Oncology.
2019
Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202
.
Journal of Clinical Oncology.
2018
Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2
.
Journal of Clinical Oncology.
2017
Show more
Contact
full name
J. L.
Wade
Quick Info
Publications
Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.
Collaboration
Co-author network
Map of science
Picked up by
10
news outlets
Posted by
20
X users
On
2
Facebook pages
185
readers on Mendeley
See more details
Picked up by
5
news outlets
Posted by
27
X users
On
1
Facebook pages
Referenced in
1
clinical guideline sources
135
readers on Mendeley
See more details
Picked up by
12
news outlets
Blogged by
1
Posted by
20
X users
On
1
Facebook pages
49
readers on Mendeley
See more details
Picked up by
8
news outlets
Posted by
69
X users
On
2
Facebook pages
Referenced in
2
clinical guideline sources
159
readers on Mendeley
See more details
Posted by
1
X users
Referenced in
1
clinical guideline sources
61
readers on Mendeley
See more details
Posted by
1
X users
42
readers on Mendeley
See more details